The somatic mode: doing good in targeted cancer therapy

Bogicevic, Ivana; Rohrberg, Kristoffer Staal; Høgdall, Estrid; Svendsen, Mette N.

doi:10.1080/14636778.2020.1799345

Cited by 8 publications

(4 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They also followed patients to the ultrasound department, observing radiologists performing the needle biopsies from metastatic lesions, which were then sent to the genomic laboratory conducting the genomic sequencing of the tumour tissue and analysing the output. Ivana joined the molecular biologists as they extracted DNA from the tissue samples, to be analysed using next‐generation sequencing technology and presented in genomic reports at bi‐weekly molecular tumour board meetings (Bogicevic et al, 2020). The Mie, Sara, and Ivana participated in these meetings, observing how an interdisciplinary team of oncologists, molecular biologists, pathologists, and a clinical geneticist deliberated to match patients to targeted treatments based on the genomic profiles of their tumours.…”

Section: Methodsmentioning

confidence: 99%

“…Yet, to make hopeful patients available for targeted trials, the phase 1 oncologists need to ensure that metastatic tissue is available for genetic analysis (see also Bogicevic et al, 2020). Karen's metastasis was not only accessible for biopsies, but the genomic analysis also showed what the phase 1 oncologists sometimes referred to as 'a needle in a haystack'-a known oncogenic mutation and an available slot in a trial targeting this specific mutation.…”

Section: Precision Patients As Keys To the Uncharted Territory Of Pre...mentioning

confidence: 99%

See 1 more Smart Citation

Precision patients: Selection practices and moral pathfinding in experimental oncology

Dam

Green

Bogicevic

et al. 2022

Sociology Health & Illness

Self Cite

View full text Add to dashboard Cite

This paper addresses selection practices in a Danish phase 1 unit specialised in precision medicine in the field of oncology. Where precision medicine holds the ambition of selecting genetically fit medicine for the patient, we find that precision medicine in the early trial setting is oriented towards selecting clinically and genetically fit patients for available treatment protocols. Investigating how phase 1 oncologists experience and respond to the moral challenges of selecting patients for early clinical trials, we show that inclusion criteria and patient categories are not always transparent to patients. Lack of transparency about inclusion criteria has been interpreted as morally problematic. Yet drawing on social science studies of ‘unknowing’, we argue that silence and non‐transparency in interactions between oncologists and patients are crucial to respect the moral agency of patients at the edge of life and recognise them as belonging to the public of Danish health care. In the discussion, we consider the practice of placing ‘unfit’ patients on a waiting list for trial participation. Rather than representing an ethical and political problem, we argue, the waiting list can act as a valve enabling oncologists to navigate the scientific and as well as the moral uncertainties in phase 1 oncology.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Precision Patients As Keys To the Uncharted Territory Of Pre...mentioning

confidence: 99%

Precision patients: Selection practices and moral pathfinding in experimental oncology

Dam

Green

Bogicevic

et al. 2022

Sociology Health & Illness

Self Cite

View full text Add to dashboard Cite

show abstract

“…2021 ). Similarly, Bogicevic and colleagues (2020) study of experimental cancer care in Danish healthcare identified two distinct “modes of doing good” via germline and somatic genomic information. Through these patterns and ideals, what counts as good in one mode might be evaluated differently in another mode or context.…”

Section: Doing and Feeling Good In Cancer Genomicsmentioning

confidence: 99%

“…We describe how the affectively good (e.g. the “feel good” nature of the project) and different modes of “doing good” ( Bogicevic et al . 2020 ) manifest the tensions, ambivalence and conflicts felt by practitioners as they sought to articulate “good” science and care within US biomedical markets and healthcare finance systems they viewed as paradoxical, contradictory and flawed.…”

Section: Introductionmentioning

confidence: 99%

“Doing Good” in U.S. Cancer Genomics? Valuation practices across the boundaries of research and care in rural community oncology

Darling

Kohut

Leeds

et al. 2022

New Genetics and Society

View full text Add to dashboard Cite

Genomic Tumour Testing (GTT) is an emerging site of “experimental care” in oncology [Cambrosio, Alberto, Peter Keating, Etienne Vignola-Gagné, Sylvain Besle, and Pascale Bourret. 2018a. “Extending Experimentation: Oncology’s Fading Boundary Bbetween Research and Care.” New Genetics and Society 37 (3): 207–226. doi: 10.1080/14636778.2018.1487281 ]. Few efforts to implement GTT have reached community oncology practices or patients living in rural communities within the US. Drawing on interdisciplinary research on a state-wide cancer genomics initiative in the rural US state of Maine, this paper explores the valuation practices within community oncologist and cancer stakeholders accounts of “doing good” within genomic science and care. We contribute to STS literatures on the bio-economy by highlighting the affective dimensions of strategies for managing economic and non-economic values. Clinician and stakeholders negotiated de-economizing and capitalizing modes of doing good as they built local genomic platforms “for Maine.” These situated modes of doing good and feeling good via cancer genomics shaped how they navigated the ethical ambiguities of US biomedical markets across the boundaries of research and care.

show abstract

Signs of Nothing: Negotiations Over Semiotic Indeterminacy in Danish Lung Cancer Diagnostics

Frumer

2023

Medical Anthropology

View full text Add to dashboard Cite

The somatic mode: doing good in targeted cancer therapy

Cited by 8 publications

References 41 publications

Precision patients: Selection practices and moral pathfinding in experimental oncology

Precision patients: Selection practices and moral pathfinding in experimental oncology

“Doing Good” in U.S. Cancer Genomics? Valuation practices across the boundaries of research and care in rural community oncology

Signs of Nothing: Negotiations Over Semiotic Indeterminacy in Danish Lung Cancer Diagnostics

Contact Info

Product

Resources

About